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Background: The interaction surface of 
coactivators and the androgen receptor (AR) is 
an important target for prostate cancer 
therapeutics. 
Results: A new interface formed by binding of 
the sequence (GARRPR) and the allosteric 
pocket (BF-3) of the AR has been identified. 
Conclusion: GARRPR binding modulates AR 
activity. 
Significance: The GARRPR/BF-3 interaction is 
a novel regulatory hub for AR activity.  
 
ABSTRACT 
The androgen receptor (AR) is a ligand-
activated transcription factor that is essential 
for prostate cancer development. It is 
activated by androgens through its ligand-
binding domain (LBD) that consists 
predominantly of 11 alpha helices. Upon 
ligand binding, the last helix is reorganized to 
an agonist conformation termed activator 
function-2 (AF-2) for coactivator binding. 
Several coactivators bind to the AF-2 pocket 
through conserved LXXLL or FXXLF 
sequences to enhance the activity of the 
receptor. Recently, a small compound-binding 
surface adjacent to AF-2 has been identified 
as an allosteric modulator of the AF-2 activity 
and is termed binding function-3 (BF-3). 
However, the role of BF-3 in vivo is currently 
unknown and little is understood about what 
proteins can bind to it. Here we demonstrate 
that a duplicated GARRPR motif at the N-
terminus of the cochaperone Bag-1L 
functions through the BF-3 pocket. These 
findings are supported by the fact that a 
selective BF-3 inhibitor or mutations within 
the BF-3 pocket abolish the interaction 
between the GARRPR motif(s) and the BF-3. 
Conversely, amino acid exchanges in the two 
GARRPR motifs of Bag-1L can impair the 
interaction between Bag-1L and AR without 
altering the ability of Bag-1L to bind to 
chromatin. Furthermore, the mutant Bag-1L 
increases androgen-dependent activation of a 
subset of AR-targets in a genome-wide 
transcriptome analysis, demonstrating a 
repressive function of the GARRPR/BF-3 
interaction. We have therefore identified 
GARRPR as a novel BF-3 regulatory 
sequence important for fine-tuning the 
activity of the AR.  
Androgens regulate both normal and malignant 
prostate cell growth and proliferation by binding 
to the androgen receptor (AR), a ligand-
inducible factor that belongs to the family of 
nuclear receptors (1–3). Like other members in 
this family, the AR has a modular structure. It 
consists of an N-terminal domain for 
transactivation (subdivided into transactivation 
units 1 and 5; τ1: amino acids 100-360 and τ5: 
amino acids 360-528), a highly conserved 
central DNA-binding domain (DBD) and a 
carboxy-terminal ligand-binding domain (LBD) 
(4).  
The LBD of most nuclear receptors, including 
the AR, consists of 12 alpha helices (numbered 
1-12; although helix 2 is missing in the AR 
compared to other nuclear receptors). Upon 
hormone binding, the 12th helix is reorganized 
to an agonist conformation generating a 
hydrophobic surface termed activation function-
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2 (AF-2) for coactivator binding. Several 
coactivators bind to this hormone-induced 
conformation via a conserved “LXXLL” 
sequence to enhance the transcriptional activity 
of the receptor (5–7). In addition, the AF-2 binds 
strongly to a 23FQNLF27 motif at its N-terminus 
(8–11) to generate an N/C-terminal 
intramolecular interaction for alternative 
coactivator binding (4, 12). More recently a 
topologically distinct surface adjacent to, but 
different from AF-2, has been identified in a 
screen of chemical libraries for small coactivator 
inhibitors. This surface has been proposed as an 
additional protein binding site for AR regulatory 
proteins and has been termed binding function-3 
(BF-3) (13). However, not much is known about 
its in vivo function except that it may be a site 
for protein-protein interaction. 
One of the factors known to modulate the 
activity of the AR is the cochaperone Bag-1L. 
This cochaperone belongs to a family of 
polypeptides translated from the same mRNA by 
a leaky scanning mechanism generating four 
isoforms in humans (Bag-1L, Bag-1M, Bag-1 
and Bag-1S) (14, 15). These isoforms differ in 
their N-terminal sequences but have a conserved 
C-terminal domain (otherwise known as the 
BAG domain) with which they bind the 
molecular chaperone Hsp70/Hsc70 as nucleotide 
exchange factors (16, 17). Besides Hsp70/Hsc70 
binding, the Bag-1 proteins interact with and 
regulate the activities of several cellular proteins 
ranging from Bcl-2 and steroid receptors to 
growth factor receptors (18). Bag-1L, the largest 
member of this family possesses a N-terminal 
nuclear localization sequence (NLS) and is 
therefore localized to the nucleus where it 
functions as a transcriptional regulator (15, 19, 
20).  
Immunohistological studies have shown that 
Bag-1L is expressed in the basal cells of benign 
prostate tissue but the site of its expression is 
changed in prostate carcinoma to the secretory 
epithelium where the AR is expressed (21). The 
AR and Bag-1L are therefore expressed in the 
same cell-type in prostate carcinoma suggesting 
a mechanistic link between the two proteins in 
this disease. Furthermore, overexpression of 
Bag-1L potentiates the transactivation action of 
the AR and domain mapping experiments have 
shown that the C-terminal region of Bag-1L 
contributes to the enhancement of the receptor 
activity (22, 23). While deletion or single amino 
acid substitutions within the C-terminus abolish 
the ability of Bag-1L to enhance AR activity and 
to bind Hsp70/Hsc70 (24), our earlier studies 
suggest that sequences other than those in the C-
terminal region may contribute to the regulation 
of AR activity (21). 
In this report we have identified a novel 
hexapeptide repeat sequence GARRPR in the N-
terminal region of Bag-1L as an additional 
interaction site for AR and have shown that it 
functions through the BF-3 pocket in the AR-
LBD. We have further demonstrated that 
mutations in the hexapeptide motifs impair 
binding of Bag-1L to the AR and differentially 
alter the androgen response of the receptor. The 
GARRPR sequence therefore defines a novel 
regulatory motif for modulating the activity of 
the AR through the BF-3 domain. 
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EXPERIMENTAL PROCEDURES 
 
Plasmids - pcDNA3-Bag-1L and pGex4T.1-
Bag-1L were provided by J. Reed. pcDNA3.1-
HA-BagN128 was generated by PCR 
amplification of the first 128 amino acids of 
Bag-1L and cloned into the pcDNA3.1-HA 
vector. pGex3X-Bag-1L∆C and pGex4T.1-Bag-
1L(1-127) were previously described (21). 
pGex-Bag-1L(1-80), (1-60), (1-40), (1-20), (21-
80), (41-80) and (61-80) were generated by PCR 
amplification of Bag-1L and cloned into the 
pGex4T.1 vector. Similarly, pGex4T.1-HAP1, -
NcoA4, PAK6, -RP9, -RRP36, -HAP1(G/P), -
PAK6(G/P), -NcoA4(G/P), -RP9(G/P), -
RRP36(G/P) were cloning into pGex4T.1. AR 
domains AF1, τ5, the hinge region and the DBD 
were cloned into pET28-GB1 vector. pET28-
AR-LBD and Gal4DBD-AR-LBD mutants were 
provided by Eva Estébanez-Perpiñá. For the 
mammalian two-hybrid assay, BagN128 was 
cloned in frame with the Gal4VP16 
transactivation domain in the pVP16 vector 
(Clontech). Gal4DBD-AR-LBD and pVP16-AR 
TAD were previously described (25). pGL3-
MMTV and Ubi-Renilla luciferase constructs 
have already been described (26, 27). pG5∆E4-
38Luc has also been described (28). pSG5-AR 
was provided by Jorma J. Palvimo. Plasmids 
poZC, pCG-gagpol and PCG-VSV-G for 
retroviral production were a kind gift from 
Guillaume Adelmant, while poZC-Bag-1L wild-
type or N-terminal mutant were cloned in house. 
 
Cell Culture and stable transfection - LNCaP 
cells were cultured in RPMI 1640 medium 
(GIBCO) and MCF7, T47D and HeLa cells in 
Dulbecco’s modified Eagle’s medium (DMEM, 
GIBCO) supplemented with 10% fetal bovine 
serum (FBS) at 37 °C with an atmosphere of 5% 
CO2. Stable transfections were carried out using 
FuGene 6 transfection reagent (Roche 
Diagnostics) according to the manufacturer’s 
protocol and stable transfectants were selected 
with geneticine (G418, Sigma-Aldrich). For 
stable retroviral transfection, 293T cells 
(cultured in DMEM, 10% FBS) were transfected 
with the retroviral vectors pCG-gagpol, pCG-
VSV-G and the poZC constructs (poZC alone, 
poZC-Bag1L or poZC-Bag1LNmut), using 
Superfect transfection agent (Qiagen) according 
to the manufacturer’s protocol. Subsequently, 
LNCaP cells were infected with the virus and 
selected using magnetic beads (M-450 
Dynabeads, Invitrogen) coupled with IL-2-
antibody (Millipore).  
 
Proximity Ligation Assay (PLA) - LNCaP cells 
were starved for 72 h and then treated with 
vehicle or 10 nM DHT for 4 h. Cells were fixed 
and permeabilized using 4% paraformaldehyde 
and 0.2% Triton X-100. LNCaP cells were then 
blocked with 10% FBS and incubated with anti-
AR (N-20, Santa Cruz), -Bag-1 (CC9E8, Santa 
Cruz) or -IgG (mouse IgG, BD Biosciences; 
rabbit serum, Sigma-Aldrich) antibodies. 
Protein-protein interactions were analyzed using 
Duolink-based in situ PLA (Sigma-Aldrich), 
according to the manufacturer’s instructions. 
Signals were quantified using a confocal Leica 
SPE microscope and the Duolink ImageTool. 
300 cells were analyzed per treatment.  
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Bag-1 knockdown and quantitative real-time 
PCR analysis - 1x105 LNCaP cells were 
transfected with control siRNA (sense 5’-
GGCUACGUCCAGGAGCGCACC-3’, 
antisense 5’-
GGUGCGCUCCUGGACGUAGCC-3’) or Bag-
1 siRNA (sense 5’-
AGAACAGUCCACAGGAA-3’, antisense 5’-
UCUUCCUGUGGACUGUUCU-3’) using 
HiPerFect transfection reagent (Qiagen) 
according to the manufacturer’s protocol. Cells 
were then starved and treated with 100 nM DHT 
for 16 h. Thereafter, cells were harvested and 
lysed in NP-40 buffer (20 mM Tris-HCl pH 8.0, 
400 mM NaCl, 1 mM EDTA, 1% NP-40, 0.1% 
SDS and protease inhibitors) for SDS-PAGE and 
Western blotting. Alternatively, cells were taken 
up in PeqGold RNApure (PeqLab 
Biotechnologie) or Trizol (Invitrogen) for RNA 
preparation using the RNaesy Mini purification 
kit (Qiagen). cDNA was synthesized for use in 
real-time quantitative PCR (qRT-PCR) analysis 
with either QuantiTect Reverse Transcription kit 
(Qiagen) or using enzymes and buffers for 
cDNA synthesis from Promega.  
 
Gene expression and microarray analysis - 
LNCaP cells stably expressing poZC vector, or 
poZC-Bag-1L wild-type or mutant were starved 
for 72 h and then treated with vehicle or 10 nM 
DHT for 4 h. Subsequently, total RNA was 
isolated as described above. Biological triplicate 
RNAs were hybridized to human U133 plus 2.0 
expression array (Affymetrix) at the Dana-
Farber Cancer Institute (DFCI) Microarray Core 
Facility. Gene expression data was normalized 
and log-scaled using the RMA algorithm (29) 
and the RefSeq probe definition (30). For genes 
with more than one probeset, the probeset with 
the highest average expression was used for 
further analysis. Differentially expressed genes 
were determined by Linear Models for 
Microarray Data (LIMMA) algorithm (31). The 
microarray data have been submitted to the Gene 
Expression Omnibus (GEO) repository under the 
accession number GSE51524. 
 
GST pull-down experiments - Expression of 
GST-tagged proteins and GST pull-down 
experiments were performed as previously 
described (32, 33).  
 
Chromatin-Immunoprecipitation (ChIP), ChIP-
re-ChIP and co-IP - LNCaP cells were starved 
for 72 hours and then treated with DHT or 
vehicle for 4 h. Thereafter ChIP was performed 
as previously described (34, 35) using following 
antibodies: anti-AR (N20, Santa Cruz), Bag-1L 
(36) and HA-tag (ab9110, Abcam). As a control, 
rabbit IgG (Santa Cruz) was employed. ChIP 
DNA was purified using the PCR purification kit 
(Qiagen) and quantified using the Quant-iT 
dsDNA HS assay kit (Invitrogen).  
ChIP-re-ChIP was carried out as described for 
ChIP, with following alterations: After the initial 
round of overnight IP (with AR, Bag-1L or IgG 
antibody), the magnetic beads were incubation in 
10 mM DTT for 30 min at 37 °C. Subsequently, 
the DTT was quenched with RIPA buffer (10 
mM Tris-HCl pH 7.5, 1 mM EDTA pH 8.0, 
0.1% SDS, 1% Triton X-100, 0.1% NaDOC and 
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protease inhibitors) with 0.3 M NaCl. Free 
chromatin complexes were then subjected to a 
second IP using different antibodies of choice. 
Endogenous co-IP was carried out as 
previously described (37) with following 
alterations: After nuclear lysis and overnight 
incubation with anti-Bag-1L or HA-tag antibody, 
protein complexes were precipitate with 
magnetic beads. Beads were then washed five 
times, 10 min each, and complexes eluted by 
boiling in Laemmli sample buffer (Bio-Rad). 
 
Fluorescence Polarization - For the 
fluorescence polarization experiments, 5 nM 
fluorescently-labeled Bag-1L (Bag-1L(1-20): 
FITC-MAQRGGARRPRGDRERLGSR, Bag-
1L(61-80): FITC-
RGAAAGARRPRMKKKTRRRS) or SRC-2 
peptide (FITC-
HDSKGQTKLLQLLTTKSDQM) were 
incubated with serially diluted AR-LBD (4 to 0.4 
µM) in binding buffer (50 mM NaPO4 pH 6.5, 
50 mM KCl, 1 mM DTT) and 10 µM DHT. The 
samples were then equilibrated for 45 min at 
ambient temperature. For the competition 
experiments, 400 to 0.4 nM of Bag-1L core 
(GARRPR) or SRC-2 peptides 
(HDSKGQTKLLQLLTTKSDQM) were 
incubated with 4 µM AR-LBD and 5 nM 
fluorescent Bag-1 or SRC-2 peptide. Binding 
was measured using polarization (excitation λ= 
485 nm, emission λ= 530 nm) on a Synergy H1 
Hybrid Reader (Biotek). 
 
Synthesis of 2-((2-(2,6-dimethylphenoxy) 
ethyl)thio)-1H-benzo[d]imidazole - The BF-3 
inhibitor 2-((2-(2,6-dimethylphenoxy)ethyl) 
thio)-1H- benzo[d]imidazole was synthesized in 
house essentially as described (38), with minor 
modifications in the addition of 1H-
benzimidazole-2-thiol to 2-(2-bromoethoxy)-1,3-
dimethylbenzene in the presence of potassium 
iodide and carbonate. The latter reactant was 
synthesized by allowing 1,2-dibromoethane to 
react with a commercially available 2,6-
dimethylphenol in the presence of potassium 
carbonate as a base at 60 °C, as previously 
described (39).  
 
Molecular modeling - The GARRPR peptide and 
CPD49 were docked into the BF-3 pocket of AR 
using DOCK 3.5.54 (40, 41). Six AR complex 
structures (PDB IDs, 2PIT, 2PIU, 2PIV, 2PIW, 
2PIX, and 2PKL) (42) were used individually in 
order to capture receptor conformational 
flexibility. For each docking experiment, the 
protein in one complex structure was used as the 
rigid receptor, with all of the waters removed. 
The original ligand in the corresponding 
complex crystal structure was used to generate 
the matching spheres. Multiple conformations of 
the peptide and CPD49 were pre-generated and 
placed in the binding pocket guided by the 
matching spheres. Ligand poses were scored 
through a grid-based method calculating van der 
Waals forces, electrostatic interactions and the 
ligand desolvation energy. The highest-ranking 
poses from each of the six docking experiments 
were combined and visually examined in the 
context of their respective receptor environment. 
The best pose was chosen based on its polar and 
non-polar interactions between the ligands and 
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the receptor, as well as the shape 
complementarity with the binding pocket. 
 
RESULTS 
Bag-1L is important for AR action - To study 
the significance of the regulation of AR action 
by Bag-1L, we first determined whether these 
two proteins interact in LNCaP prostate cancer 
cells using co-immunoprecipitation. We were 
able to detect AR by Western blotting when 
Bag-1L was immunoprecipitated, both in the 
absence and presence of the androgen 
dihydrotestosterone (DHT) (Fig. 1A). We could 
additionally show that Bag-1 and AR interact in 
LNCaP cells by an in situ proximity ligation 
assay (43). This assay uses oligonucleotide-
generated high intensity fluorescent signals to 
assess in situ whether two proteins are located in 
close proximity to one another. The ligation 
assay performed with Bag-1 (that recognizes all 
Bag-1 isoforms) and AR antibodies showed 
positive punctuated perinuclear signals in the 
LNCaP cells in the absence and presence of 
DHT. However, the number of fluorescence 
signals per nucleus was slightly enhanced in the 
presence of the hormone (Fig. 1B). Little or no 
fluorescent signals were observed when AR or 
Bag-1 antibodies were used together with an 
isotype IgG control antibody.  
To determine the contribution of Bag-1L to AR 
response, we next downregulated the expression 
of Bag-1 in LNCaP cells using RNA interference 
and determined the expression of two well-
studied, androgen-regulated genes, PSA and 
FKBP5 (44). siRNA transfection significantly 
reduced the level of expression of the Bag-1 
isoforms (Fig. 2A). Concomitant with this 
reduction was a downregulation of the androgen-
mediated transcription of the two genes, which 
was highly significant for FKBP5 (Fig. 2B). This 
shows that Bag-1 proteins contribute to an 
efficient, androgen-mediated transcription. 
Next we investigated whether Bag-1L is 
recruited to AR enhancer regions of the PSA and 
FKPB5 genes using a Bag-1L-specific antibody 
(36). We were able to identify solo occupancy of 
either AR (Fig. 2C) or Bag-1L (Fig. 2D) using 
chromatin immunoprecipitation (ChIP). 
Furthermore, we could demonstrate a partial co-
occupancy of Bag-1L and AR at these enhancer 
elements, shown by a comparable or increased 
fold enrichment in the ChIP-re-ChIP relative to 
the solo ChIP (compare Fig. 2C with 2E and 2D 
with 2F) (45). No co-occupancy of the two 
proteins was observed in the re-ChIP 
experiments when the antibody for either of the 
proteins was substituted with IgG (data not 
shown).  
 
Bag-1L interacts with the AR - To determine 
which Bag-1L domains are important for AR 
binding we carried out pull-down experiments 
with GST-fused truncations of Bag-1L and 
lysate from androgen-treated LNCaP cells (Fig. 
3A). We could confirm the results of Knee et al., 
2001, which showed that the C-terminal domain 
of Bag-1L binds the AR (Bag-1LΔ214, construct 
5; Figs. 3B and 3C). Similarly, all other Bag-1L 
constructs containing this part of the protein also 
bound the AR (Bag-1LΔ115 and Δ122, 
constructs 3 and 4; Fig. 3B). Intriguingly, a 
construct lacking the C-terminus altogether also 
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interacted with the AR (Bag-1LΔC, construct 2; 
Fig. 3B). This binding could be traced to the first 
128 N-terminal amino acids of Bag-1L 
(BagN128, construct 6) since amino acids 141 to 
298 failed to bind the receptor (BagULD, 
construct 7; Fig. 3C). We have therefore 
identified an additional interaction site for AR 
on the N-terminus of Bag-1L.  
To show that the BagN128/AR interaction can 
also occur in cells (in situ), we performed a 
mammalian one-hybrid assay in HeLa cells 
where we transfected a construct coding for a 
Gal4DBD-BagN128 fusion or just Gal4DBD 
alone together with a Gal4 binding site-
luciferase reporter gene and an AR expression 
vector. The transfected cells were then treated 
with or without DHT and the reporter gene 
activity was measured. A basal reporter gene 
activity was observed for the Gal4DBD alone or 
in combination with AR, independent of 
androgen treatment. However, when Gal4DBD-
BagN128 and AR were transfected together, an 
increase in the reporter gene activity was 
observed in the presence of DHT (Fig. 3D). This 
demonstrates a cellular interaction of the N-
terminal sequence of Bag-1L with AR in the 
presence of hormone. 
 
A duplicated hexapeptide motif for AR binding 
- The N-terminal sequence of Bag-1L 
(BagN128) consists of an unidentified sequence, 
the NLS and a TR/QSEEX repeat region 
(construct 1; Fig. 4A). To determine precisely 
which region is responsible for AR binding, we 
carried out GST pull-down experiments utilizing 
deletion mutants of BagN128 (Fig. 4A) and 
lysate of androgen-treated LNCaP cells. Our 
results show that AR binding is localized to the 
1-80 but not to the 81-128 amino acids of Bag-
1L (constructs 2 and 3; Fig. 4B). Further C- and 
N-terminal truncations of the 1-80 amino acid 
sequence all interacted with the AR. The 
smallest peptides bound by the AR were 
identified as amino acids 1-20 and 61-80 
(constructs 6 and 9; Fig. 4B).  
The only identical feature that could explain 
why these two peptides bind the AR is a motif 
“GARRPR” that is present in both sequences 
(Fig. 4C). We therefore postulated that the 
GARRPR motif is the interaction site of the AR. 
To validate this, we substituted the hexapeptide 
sequence with alanine residues and repeated the 
above-described GST pull-down assay (Figs. 4D 
to 4F). These alanine substitutions completely 
abolished the interaction between the Bag-1L 
peptides and the AR, confirming the importance 
of the GARRPR motif for AR binding (Figs. 4E 
and F: compare constructs 3 with 4 and 5 with 
6). To determine the selectivity of this 
hexapeptide sequence for the AR compared to 
other nuclear receptors, we repeated the GST 
pull-down assays substituting LNCaP cell lysate 
for those from MCF7, HeLa or T47D cells (Fig. 
4G). These lysates contain high levels of 
estrogen (ERα), glucocorticoid (GR) or 
progesterone receptors (PR), respectively. ERα 
proved similar to AR in recognizing the 
GARRPR motif (Fig. 4G, top row). However, 
although GR and PR bound both the 1-128 and 
the 1-80 N-terminal peptides of Bag-1L, they 
failed to bind the two shorter peptides 
(constructs 3 and? 5; Figs. 4D and 4G), 
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suggesting that their binding sites are localized 
outside these two sequences. 
 
The GARRPR motif binds the AR-LBD - To 
determine the region of the AR that binds the 
GARRPR motif, fluorescence polarization 
experiments were carried out with the two Bag-
1L peptides (amino acids 1-20 and 61-80) 
labeled with fluorescein isothiocyanate (FITC), 
and purified domains of the AR covering the 
hinge-LBD (amino acids 646-919), the τ5 region 
(amino acids 360-548), the DBD (amino acids 
552-636), the hinge region (amino acids 610-
685) and, as a control, GST. Both Bag-1L 
peptides bound the hinge-LBD (Fig. 5A) but not 
the other AR domains or the GST control (data 
not shown). The binding affinities of the Bag-1L 
peptides for the AR-LBD were estimated by 
Sigma plot to be KD = 2.0 ± 0.6 µM for Bag-
1L(1-20) and 3.3 ± 1.3 µM for Bag-1L(61-80). A 
positive control peptide, the high affinity nuclear 
receptor box of SCR-2 that contains the LXXLL 
core motif (46), also bound the AR-LBD with 
comparable affinity (KD = 2.8 ± 1.6 µM; Fig. 
5B). Given the similar affinities of the Bag-1L 
and SRC-2 peptides for AR-LBD, we questioned 
if these peptides could directly compete for 
binding to the AR-LBD. In line with our 
hypothesis, binding of the GARRPR-containing 
Bag-1L peptides to the AR-LBD could be 
outcompeted by SRC-2 (Fig. 5C) and 
conversely, SRC-2 binding was outcompeted by 
an unlabeled GARRPR core sequence (Fig. 5D). 
These results suggest that the binding sites of the 
Bag-1L and SRC-2 peptides must be similar or 
in close proximity to one another. Alternatively, 
binding of one of the peptides may allosterically 
hinder binding of the other.  
 
The Bag-1L peptides interact with the BF-3 
pocket of the AR-LBD - Detailed studies of the 
AR AF-2 have shown that it forms an interaction 
surface for LXXLL-binding proteins or proteins 
with LXXLL variants with bulky aromatic 
hydrophobic groups such as FXXLF (11, 47). 
Given the highly charged nature of the GARRPR 
motif, it is therefore unlikely that it interacts 
with the AF-2 domain. It is more likely that it 
interacts with the recently described BF-3 
domain, which is found next to the AF-2 and 
which allosterically modulates the activity of this 
domain.  
Interaction of peptides to BF-3 has been 
difficult to demonstrate, but more recently a 
group of ligand derivatives of 2-((2-
phenoxyethyl) thio)-1H-benzimidazole was 
shown to bind specifically to the BF-3 pocket of 
the AR (38, 48). One of these ligands is 2-((2-
(2,6-dimethylphenoxy)ethyl)thio)-1H-
benzo[d]imidazole (compound 49 (CPD49); Fig. 
6A) that exerts significant anti-androgen potency 
in LNCaP and Enzalutamide-resistant prostate 
cancer cell lines (38, 48). We therefore used this 
ligand to determine whether it would compete 
with the GARRPR peptides for binding to the 
BF-3 pocket.  
In a mammalian two-hybrid assay in which we 
determined binding of the GARRPR-containing 
Bag-1L peptides to the AR-LBD, CPD49 had no 
significant inhibitory effect on the activity of the 
LBD alone (Fig. 6B; black line) but potently 
inhibited the interaction of the Bag-1L peptides 
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with the LBD with IC50 values of 4 and 10 µM 
for Bag-1L(1-20) and Bag-1L(61-80), 
respectively (Fig. 6B; blue and red lines). This 
compares favorably to the IC50 values of 3.3 and 
6.8 µM for the inhibition of PSA secretion in 
LNCaP and Enzalutamide-resistant LNCaP cell 
lines, respectively (13, 38)(13, 38)(13, 38)(13, 
38).  
Our molecular modeling studies show that 
CPD49 binds to the BF-3 domain by making 
extensive non-polar contacts with amino acids 
F673, P723, and F826 that form the BF-3 
pocket, in addition to favorable electrostatic 
interactions between its nitrogen atom and E837 
of the BF-3 (Fig. 6C). CPD49 binding would 
therefore likely interfere with the binding of the 
peptides to the BF-3 domain since the proline 
residue of the peptide core (GARRPR) prefers to 
sit in the hydrophobic cavity of the BF-3 domain 
(Fig. 6D). In addition, favorable electrostatic 
interactions appear to occur between the G(1), 
A(2), R(3), R(4) and R(6) of the peptide core 
with amino acids E837, N727, G724, E829 and 
E837 that form the BF-3 pocket (Fig. 6D). 
To further confirm the interaction of the Bag-
1L peptides with the BF-3 domain, we 
performed a mammalian two-hybrid assay with 
Gal4DBD fused to the wild-type AR-LBD or 
LBD domains harboring mutations in the BF-3 
pocket (Fig. 6E). These mutations either line the 
BF-3 pocket itself (F826, L830, N833, R840) or 
are at the boundary of the BF-3 and AF-2 
domains (R726) (13, 49, 50). In addition, we 
included mutant V757, which is located at the 
end of helix 5 of the AR-LBD outside the BF-3 
pocket (49). Although the Bag-1L(1-20) and 
Bag-1L(61-80) peptides interacted with the wild-
type AR-LBD, their interaction with most of the 
BF-3 mutants was strongly compromised (Fig. 
6E). The only exception was the interaction with 
F826, where a substitution of an arginine (R) 
suppressed but did not abolish binding of the 
Bag-1L peptides to the AR-LBD. This F826R 
mutation has previously been reported to have an 
anomalous behavior in interaction studies with 
other coactivators (49). The control mutation at 
V757 did not affect binding of the Bag-1L 
peptides (Fig. 6E). Together these results 
strongly suggest that the BF-3 pocket is an 
essential domain for the interaction of the Bag-
1L peptides with the AR-LBD. 
 
Identification of a signature motif - A systematic 
analysis of the contribution of the individual 
residues in the hexapeptide motif of Bag-1L was 
carried out to determine the exact binding 
signature for Bag-1L to the AR. Each amino acid 
in the GARRPR cores of Bag-1L(1-20) and Bag-
1L(61-80) was consecutively substituted with 
alanine residues. These mutants were then fused 
to GST and used in a pull-down assay with 
lysate from LNCaP cells previously treated with 
or without androgen. Androgen-mediated 
binding was destroyed when any single amino 
acid of the core residues GARRPR was 
exchanged for alanine moieties in the Bag-1L(1-
20) peptide (Fig. 7A). This was however not the 
case for the Bag-1L(61-80) peptide where only 
the exchange of the penultimate two amino acids 
xxxRPx to alanine decreased binding (Fig. 7B).  
In a subsequent attempt to define the 
contribution of the individual residues in the 
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hexapeptide motif, protein blast search was 
carried out to determine whether homologies of 
the Bag-1L GARRPR sequence exist in other 
proteins. Over 70 proteins with near complete or 
partial homologies were identified and peptides 
encompassing the homologous regions were 
synthesized. These peptides were then spotted 
onto membranes using an automated SPOT 
synthesizer (51) and hybridized to (bacterially-
purified) AR-LBD. A wide variety of peptides 
containing complete to partial homology to the 
hexapeptide core were found to interact with the 
AR-LBD (Fig. 7C and Supplementary Table 1). 
A sequence logo derived from the validated 
peptide sequences identified G(1) and P(5) as the 
crucial residues for AR binding (Fig. 7D). 
To further confirm the contribution of G(1) and 
P(5) within the GARRPR motif for binding to 
the AR-LBD, some positively identified peptides 
from the SPOT assay were further validated in a 
GST pull-down experiment. These included the 
ribosomal RNA processing protein 36 (RRP36), 
retinitis pigmentosa 9 (RP), huntington 
associated protein 1 (HAP1), nuclear receptor 
coactivator 4 (NcoA4) and p21 protein 
(Cdc42/Rac9-activated kinase 6 (PAK6)), the 
latter three of which are known to bind the AR 
(52–54). These peptides mostly show complete 
sequence identity with the core GARRPR, with 
the exception of NcoA4 and PAK6, which only 
share 2-3 homologous residues (but including 
G(1) and P(5)) with the GARRPR motif. We 
could confirm a hormone-dependent binding of 
all the peptides to the AR with the exception of 
PAK6, where binding was weaker in the 
presence than in the absence of hormone (Fig. 
7E). Since PAK6 and NcoA4 contain only 
limited homologies to the GARRPR core, it is 
likely that only the conserved amino acids at 
positions 1 and 5 (GxxxPx) contribute to the 
interaction with the AR-LBD. In GST pull-down 
experiments we could confirm this by 
exchanging the conserved amino acids G(1) and 
P(5) to alanine, which indeed reduced binding of 
all the peptides to the liganded AR-LBD (Fig. 
7F).  
 
The N-terminal mutant of Bag-1L is defective in 
AR binding - Having established that residues 
G(1) and P(5) in the GARRPR motif are 
essential for the interaction with the AR, we next 
investigated the effect mutations of these 
residues in the two Bag-1L peptides would have 
on their interaction with the AR. Using a GST 
pull-down assay we could show that an 
exchange of residues G(1) and P(5) with alanine 
residues destroys the androgen-dependent 
binding of both Bag-1L(1-20) and Bag-1L(61-
80) to the receptor (Fig. 8A). Furthermore, 
fluorescence polarization experiments confirmed 
that binding of the Bag-1L peptides to the AR-
LBD is reduced upon the mutation (Fig. 8B). 
We next introduced the 
G6A/P10A/G66A/P70A substitutions that 
decreased the BagN128-AR binding, into the 
full-length Bag-1L; the resulting Bag-1L protein 
has a mutated N-terminal end but an intact C-
terminal BAG-domain. We created LNCaP cells 
stably overexpressing HA-, Flag-tagged versions 
of the wild-type or mutant Bag-1L proteins, and 
as a control, LNCaP cells expressing the empty 
vector construct. Since the GARRPR mutations 
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are close to the NLS (position 70-76), as well as 
another region (amino acids 17-50) that has been 
reported to contribute to the nuclear localization 
of Bag-1L (23, 55), we carried out 
immunofluorescence microscopy to determine if 
the cellular localization of Bag-1L (or AR) is 
altered by the mutations. The 
immunofluorescence experiments showed no 
change in localization of the mutant Bag-1L 
compared with the wild-type protein (Fig. 9A), 
demonstrating that the mutations do not affect 
the nuclear localization of Bag-1L (or the AR). 
We next tested the expression levels of Bag-1L 
and AR in the stable cell lines. Bag-1L 
expression levels were comparable between the 
wild-type and mutant Bag-1L expressing cell 
lines, and Bag-1L overexpression (whether wild-
type or mutant) did not change the endogenous 
expression levels of the AR (Fig. 9B). Lastly, we 
tested the ability of the full-length, GARRPR-
mutant Bag-1L protein to interact with the AR 
by co-immunoprecipitation (Fig. 9C). We could 
not detect any significant interaction (both 
hormone-dependent or -independent) between 
the full-length Bag-1L and AR when the 
GARRPR motifs were mutated, which is in 
agreement with the findings for the mutated 
Bag-1L peptides (Fig. 8A). 
 
The N-terminal Bag-1L mutations cause 
alterations in AR transactivation - Having 
established that the GARRPR mutations impair 
the interaction of Bag-1L with AR (Fig. 9C), we 
postulated that Bag-1L-mediated regulation of 
AR action might also be affected by these 
mutations. To prove this, we performed genome-
wide gene expression profiling in the LNCaP 
Bag-1L wild-type and mutant overexpressing 
cell lines, as well as the LNCaP vector control 
cells. We focused entirely on AR-regulated 
genes by culturing the cells in the absence and 
presence of DHT and only took into 
consideration differentially expressed genes with 
a fold change of 1.75 or higher upon hormone 
treatment (and a p-value of 0.05 or less). 
Comparison of the DHT-regulated transcriptome 
of the vector, wild-type and Bag-1L mutant-
transfected LNCaP cells revealed a significant 
number of differentially up-regulated genes that 
could be clustered in five different categories 
(Fig. 10A). The total number of down-regulated 
genes was modest (n=7) and therefore these 
genes were excluded from the analysis. 
The biggest gene cluster we identified, defined 
as “all common genes”, consists of a number of 
genes that were all highly expressed (>1.75 fold) 
in all three datasets. This is in contrast to the 
next cluster (“WT+NMut only”), which only 
contains genes that were upregulated in the Bag-
1L wild-type and mutant overexpressing cells 
but showed low (< 1.75 fold) or no differential 
expression in the vector expressing cells. This 
finding is in agreement with previous studies 
that showed that Bag-1L overexpression 
potentiates the transactivation action of the AR 
(21, 22, 24). Correspondingly, gene annotation 
analysis revealed that that the genes uniquely 
upregulated in the “WT+NMut” cell lines are 
associated with changes in cell signaling and 
proliferation.  
We also identified a significant number of 
genes that were differentially transcribed across 
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all three cell lines and were therefore categorized 
as being uniquely expressed; the exception is the 
vector (Vec) category which includes two genes 
that are also expressed in the wild-type cells. 
The largest and most significant of the unique 
categories belongs to the N-terminal mutant 
overexpressing cells (NMut), which points 
towards an exclusive function of the GARRPR 
mutations in the modulation of the AR-mediated 
transcriptome. The majority (53.6%) of the 
genes identified within this group are associated 
with metabolic processes. 
We validated the expression of a select number 
of genes by qRT-PCR, which we had defined as 
being unique to the Bag-1L GARRPR mutant 
cell line (based on the microarray data). As 
expected, the expression of all tested genes was 
significantly higher in the Bag-1L mutant cell 
line compared with their respective expression 
levels in the vector and Bag-1L overexpressing 
cells (Fig. 10B). Concomitantly, AR binding at 
regulatory regions of these genes, as determined 
by AR ChIP, was higher in the Bag-1L mutant 
than in the vector or Bag-1L wild-type cells (Fig. 
10C). In comparison, Bag-1L binding remained 
unaltered at the same AR regulatory sites across 
the three different cell lines (data not shown). 
Thus, the mutation of the GARRPR motif of 
Bag-1L, which causes the inhibition of the Bag-
1L/AR interaction, triggers an increase in 
binding and activity of the AR at selected target 
genes, without altering the direct binding of Bag-
1L to chromatin. Together, our findings indicate 
that binding of Bag-1L to the AR through the 
(un-mutated) GARRPR motif contributes to the 
suppression of a subset of AR-regulated genes. 
 
DISCUSSION 
In this work we have analyzed the regulation of 
AR by the cochaperone Bag-1L. We could show 
that N-terminal amino acid sequences of Bag-1L 
bind to the AR and contribute to the 
transactivation function of the receptor. 
Furthermore, we identified a repeat hexapeptide 
motif “GARRPR” in Bag-1L as an essential 
sequence for binding to the AR-LBD. This motif 
functions through sequences that constitute the 
newly identified allosteric regulator BF-3 in the 
AR-LBD and mutations in this motif cause the 
loss of Bag-1L/AR interaction and alter the 
transactivation function of the AR. 
Previous studies to identify sequences on 
coactivators that bind the LBD of nuclear 
receptors using phage display libraries have only 
identified variants of the LXXLL motif (11, 47). 
For example, peptides bound to the AR 
coactivator binding domain include a 
combination of aromatic residues and the 
canonical leucine-rich sequence of LXXLL such 
as FXXLF, FXXLW, WXXLF, WXXVW, 
FXXFF or FXXYF (11, 47). Similarly, peptides 
that interact with the coactivator binding domain 
of another steroid receptor, the estrogen receptor 
α (ERα) can be categorized into three classes of 
LXXLL motifs that differ in their flanking 
sequences, but not in the canonical motifs 
themselves (56).  
Well-characterized AR coactivators include the 
p160/SRC family of proteins that bind to the τ5 
of the AR through a glutamine-rich sequence 
independent of their intrinsic LXXLL motifs 
(57–59). A coactivator MED1 has also been 
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shown to bind to the τ1 region at the N-terminus 
through two noncanonical α-helical motifs but 
independent of its LXXLL motifs (60). The 
GARRPR sequence we have identified in the 
present study presents yet another mode of AR 
regulation and differs both structurally and 
functionally from the LXXLL motif. First, it is 
highly charged compared to the LXXLL motif, 
which is highly hydrophobic. Second, it exhibits 
target specificity, since it binds the AR and the 
ERα, but not the GR or the PR. This is therefore 
unlike the LXXLL motif, which interacts with 
the coactivator pocket, activation function-2 
(AF-2) of several nuclear receptors, including 
the AR. However like the LXXLL motif, the 
GARRPR motif binds to the AR-LBD. 
Compellingly, our studies show that the 
interaction of the AR-LBD with the GARRPR-
containing Bag-1L peptides can be outcompeted 
with a LXXLL-containing SRC-2 peptide. 
Similarly, the AR-LBD/SRC-2 interaction can 
be competed off by a GARRPR core peptide. 
This might suggest that the GARRPR and 
LXXLL motifs bind to closely related sequences 
on the AR. Alternatively, binding by one peptide 
may produce allosteric changes in the flanking 
region of AR that may affect binding by the 
other. However, it is more plausible to us that 
the GARRPR sequence binds to the newly 
identified allosteric region of the AR-LBD 
termed binding function-3 (BF-3) (42), rather 
than the AF-2 pocket. We present three pieces of 
evidence that support this possibility. First, the 
use of a small, specific, molecule inhibitor of the 
BF-3 destroys binding of the Bag-1L peptides to 
the AR-LBD. Second, molecular modeling 
shows that the GARRPR fits into the BF-3 
pocket with the proline residue localized in the 
hydrophobic cavity of this pocket. Third, single 
amino acid exchanges in the BF-3 pocket, but 
not an outside sequence, destroy binding of the 
Bag-1L peptides to the LBD in a mammalian 
two-hybrid assay. Together these results strongly 
suggest that the Bag-1L peptides bind to the BF-
3 pocket of the AR. 
Although the BF-3 pocket has been postulated 
to bind regulatory proteins, it has thus far been 
difficult to demonstrate factor-specific binding 
to this site because of its weak affinity for 
proteins (13). So far only FKBP52, a 
cochaperone of Hsp90 that binds the AR/Hsp90 
complex and regulates ligand binding to the AR, 
has been shown to function through the BF-3 
pocket. However, a direct demonstration of 
binding is lacking (61). Studies on a possible 
interaction sequence of FKBP52 with the BF-3 
pocket suggested the involvement of alanine and 
proline residues in the sequence “GSAGSPP” at 
the N-terminus of FKBP52 (61, 62). This 
sequence is strikingly similar to the GARRPR 
motif we identified but it is completely different 
from the LXXLL coactivator motif that binds the 
AF-2 domain of the AR. Nonetheless there are 
differences in the functional consequences of the 
binding of FKBP52 and Bag-1L to the AR-LBD. 
The former binds through its N-terminal FK506 
binding domain and is required for hormone 
binding, while the latter interaction is through a 
so far uncharacterized N-terminal Bag-1L 
sequence that seems to control the 
transactivation function of the AR. Future 
structural experiments will be needed to 
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distinguish between the interactions of these two 
proteins with the BF-3 of the AR. For now, our 
results with Bag-1L agree with the notion that 
agents that bind to the BF-3 pocket allosterically 
regulate the transactivation function of the AR 
(13).  
Studies on how BF-3-lining residues affect AR 
activity show that mutations in the BF-3 pocket 
alter the ability of AF2-binding coactivators to 
modulate the transactivation function of the AR 
(49). Residues in the BF-3 pocket are also 
targets for prostate cancer and androgen-
insensitivity syndrome (AIS) mutations (63–67). 
Our finding that the GARRPR motifs of Bag-1L 
bind to the BF-3 would therefore strongly 
implicate Bag-1L in the development or 
progression of AIS and/or prostate cancer. In our 
study we could show that mutations in the 
GARRPR motif that destroy binding to the BF-3 
pocket did not inhibit AR-mediated gene 
expression, but rather increased the expression 
of a subset of androgen-regulated genes 
mediating metabolic processes. Previous studies 
on AR-mediated upregulation of genes involved 
in metabolism have pointed to a role of the AR 
in the normal prostate epithelium in driving the 
synthesis of seminal fluid (68, 69). Therefore our 
finding that the mutant Bag-1L increases the 
expression of AR-regulated genes involved in 
metabolism indicates a shift from the 
involvement of Bag-1L in promoting AR action 
in prostate cancer towards a normal prostate 
function.  
The N-terminus is not the only part of Bag-1L 
that binds the AR. The C-terminus of Bag-1L 
has been shown to bind the AR in vitro as 
identified by GST pull-down studies (21, 23). 
However our in vivo studies show a complete 
impairment of binding of Bag-1L to the AR after 
mutating the GARRPR sequence at the N-
terminus of Bag-1L. Thus, we can conclude that 
in the cellular context, the N-terminal sequence 
of Bag-1L is very important for AR binding. In 
addition, the N-terminus of Bag-1L also binds 
DNA through lysine- and arginine-rich 
sequences between amino acids 68 and 81 at its 
N-terminus (70–72). We therefore postulate that 
the association of Bag-1L with the AR, as 
demonstrated in this work, allows the (intact) 
AR/Bag-1L complexes to bind to enhancer 
elements of AR target genes (with both proteins 
binding to chromatin). However, when the Bag-
1L/AR interaction is disrupted by mutations in 
the GARRPR motifs, although the interaction of 
Bag-1L and chromatin still persists, the AR is 
now free to bind more avidly to distinct enhancer 
sequences. This would explain the increased AR 
binding and androgen response of a subset of 
genes following the overexpression of the 
mutated Bag-1L in LNCaP cells, as shown in our 
experiments.  
Our findings therefore offer an opportunity for 
studying the mechanism of repression and de-
repression in the control of AR transactivation in 
prostate cancer cells.  
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FIGURE LEGENDS 
 
FIGURE 1. AR and Bag-1L interact in situ  
 
A. Co-immunoprecipitation of endogenous Bag-1L and AR in LNCaP cells using a Bag-1L-
specific antibody for the IP and an antibody against AR, to evaluate binding. An IgG IP was 
carried out simultaneously, as a negative control. 1/10th of the input samples are shown and 
confirm equal protein loading. B. Proximity ligation assay (PLA) was performed in LNCaP cells 
treated with vehicle or 10 nM DHT for 4 h. Antibodies against AR, Bag-1 or IgG control were 
used. The quantification of the PLA dots (scored as dots per nucleus) is shown on the right. P-
values were calculated using Mann-Whitney-U-test; * p < 0.05. 
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FIGURE 2. Bag-1 is necessary for AR-dependent gene expression and co-localizes with AR 
at androgen-regulated enhancers  
 
A, B. LNCaP cells were transfected with control or Bag-1 siRNA and treated with vehicle or 100 
nM DHT for 16 h. A. Western blot of the Bag-1 knockdown using anti-Bag-1 and, as a control, 
α-Tubulin antibodies. B. qRT-PCR of PSA and FKBP5 expression in control (Ctrl.si) or Bag-1 
knockdown cells (Bag-1si). Data represent the mean of three independent experiments, each in 
duplicate ± SEM. P-values were calculated using standard t-test; ** p < 0.01. C, D. Chromatin 
immunoprecipitation (ChIP) of AR (C) or Bag-L (D) was performed in LNCaP cells treated with 
vehicle (open bars) or 10 nM DHT (closed bars) for 4 h. The results are represented as fold 
enrichment over input and are the averages of three replicates ± SD. E, F. Complex formation 
between AR and Bag-1L was analyzed by ChIP-re-ChIP, immunoprecipitating first with AR 
followed by Bag-1L ChIP (E) or by Bag-1L ChIP followed by IP with an AR antibody (F).  
 
FIGURE 3. The N- and C-termini of Bag-1L bind the AR  
 
A. Schematic diagrams of wild-type Bag-1L and its deletion mutants. B, C. GST/Bag-1L fusion 
proteins, as indicated in (A), were used in a pull-down assays with lysate from LNCaP cells 
treated with 10 nM R1881 for 20 h. AR binding was determined by Western blotting using an 
anti-AR antibody. GST-proteins were visualized using Ponceau staining. D. Luciferase assay of 
HeLa cells transfected with the indicated vector constructs and treated with vehicle (open bars) or 
100 nM DHT (filled bars) for 16 h. Data points represent the mean of three independent 
experiments ± SEM; *** p ≤ 0.005. 
 
FIGURE 4. Identification of the N-terminal AR binding site of Bag-1L 
 
A. Schematic diagrams of different truncations of the 128 N-terminal amino acids of Bag-1L. B. 
GST pull-down experiments with the GST-fusion proteins shown in (A) and LNCaP cell lysate. 
Protein binding was visualized by Western blotting using an anti-AR antibody. Equal protein 
loading was confirmed by Ponceau staining. C. The amino acid sequence of Bag-1L(1-20) and 
Bag-1L(61-80) with the GARRPR motif highlighted in blue. D. Schematic diagrams of different 
truncations of the 128 amino acids of Bag-1L, with the GARRPR motifs either intact (constructs 
1-3 and 5) or all the GARRPR amino acids converted to alanine residues (constructs 4 and 6). E. 
GST pull-down experiments with the GST-fused proteins shown in (D) and lysate from LNCaP 
cells. Western blotting was carried out using an antibody against AR. Equal protein loading was 
confirmed by Ponceau staining. F. Densitometry analysis of the AR interaction with the BagN128 
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truncations (as shown in (E)). The graph represents AR band intensities with reference to the 
AR/BagN128 interaction signal. Data points represent the mean of four independent experiments 
± SEM. G. GST pull-down experiments with the GST-fusion proteins shown in (D) and lysates 
from MCF7, HeLa or T47D cells. Binding was visualized by Western blotting using antibodies 
against ERα, GR or PR. Equal protein loading was confirmed with an anti-GST antibody. 
 
Figure 5. The GARRPR motif binds the AR-LBD 
 
A, B. Fluorescence polarization experiments using serially-diluted AR-LBD and FITC-labeled 
Bag-1L(1-20) (blue line) and Bag-1L(61-80) peptide (red line; A) or FITC-labeled SRC-2 peptide 
(green line; B). C, D. Peptide competition experiments were performed using conditions for 
maximum polarization of FITC-labeled peptide and AR-LBD. The competition was carried out 
with unlabeled SRC-2 peptide (C) or unlabeled core GARRPR hexapeptide (D).  
 
FIGURE 6. The integrity of the BF-3 domain is essential for binding of the GARRPR motif 
 
A. Structure of the BF-3 inhibitor 2-((2-(2,6-dimethylphenoxy)ethyl)thio)-1H-benzo[d]imidazole 
(CPD49). B. Luciferase assay of HeLa cells transfected with Bag-1L(1-20), Bag-1L(61-80) or a 
control vector construct and treated with different concentrations of CPD49 and 100 nM DHT for 
16 h. Data points are shown as DHT-mediated fold induction and the lines demonstrate the non-
linear regression between data points. The results are the mean of three independent experiments 
± SD. C, D. Modeling experiment between the BF-3 pocket of the AR-LBD and the BF-3 
inhibitor, CPD49 (C), or the GARRPR peptide (D). Residues of the BF-3 pocket involved in 
contact formation are indicated. E. Luciferase assay of HeLa cells transfected with indicated 
vector constructs and either wild-type AR-LBD (wt) or different AR-LBD mutants. The 
experiments were carried out in the presence of vehicle (open bars) or 16 h 100 nM DHT 
treatment (filled bars). Data points represent the mean of at least three independent experiments ± 
SEM.  
 
FIGURE 7. Identification of essential amino acids in the GARRPR motif required for AR 
binding  
 
A, B. GST pull-down experiments between the lysate from LNCaP cells treated with 100 nM 
DHT for 1 h and GST-fused Bag-1L(1-20) (A) or Bag-1L(61-80) peptides (B). Each amino acid 
of the GARRPR motif was consecutively substituted by an alanine residue (shown in red). 
Results are represented as the observed mean binding compared with Bag-1L wild-type peptide 
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binding in three independent experiments ± SEM. Open bars represent vehicle-treated and closed 
bars DHT-treated conditions. C. The Bag-1L peptide sequences and sequences of other AR-
binding proteins with the GARRPR sequence (or variants thereof) shown in red. D. Sequence 
logo of the binding motif of all peptides tested in (C) as determined by 
http://weblogo.berkeley.edu/. E. The peptides shown in (C) were GST-tagged and incubated with 
LNCaP cell lysate treated with vehicle or 100 nM DHT for 1 h. Protein binding was confirmed by 
Western blotting using an anti-AR antibody. GST-proteins were visualized using Ponceau 
staining. F. GST-tagged peptide versions of the sequences described in (C), either in their intact 
form (wt) or with the G and P of their GxxxPx motives exchanged to alanine residues (mut), were 
incubated with LNCaP cell lysate treated with 100 nM DHT for 1 h. Protein binding was 
identified by Western blotting using an anti-AR antibody. GST-proteins were visualized using 
Ponceau staining.  
 
FIGURE 8. Mutation of the GARRPR peptides decreases their binding to the AR-LBD 
  
A. GST pull-down experiments with GST-fused wild-type Bag-1L(1-20) or Bag-1L(61-80) 
peptides, or the same peptides with alanine exchanges at the G and P positions of the GARRPR 
motif. The experiment was carried out using LNCaP cell lysate treated with vehicle or 100 nM 
DHT for 1 h. Binding was analyzed by Western blotting using an anti-AR antibody. GST-proteins 
were visualized by Ponceau staining. B. Fluorescence Polarization experiments were performed 
using serially diluted AR-LBD and FITC-labeled Bag-1L(1-20) (blue line; A) or Bag-1L(61-80) 
(red line; B) and their corresponding mutant peptides as shown by black or grey lines for Bag-
1L(1-20) or Bag-1L(61-80), respectively. 
 
FIGURE 9. The integrity of the Bag-1L GARRPR motif is essential for AR binding 
A. HeLa cells were transfected with constructs for AR and HA-tagged wild-type or mutant Bag-
1L, and then treated with vehicle or 100 nM DHT for 16 h. Immunostaining was carried out with 
anti-AR or HA-antibodies. Cell nuclei were stained with Draq5. B. The Western blot of Bag-1L 
(Bag-1L, HA-tag and Flag-tag) and AR expression was performed using nuclear cell lysates of 
vector-transfected control cells (Vector) or LNCaP cells overexpressing HA-, FLAG-tagged wild-
type (WT) or N-terminal mutant Bag-1L (NMut). Cells were either treated with vehicle (-) or 
DHT (+) for 4 h prior to cell lysis. Actin levels are shown as a control of equal protein loading. C. 
Co-immunoprecipitation of Bag-1L and AR in LNCaP cells stably overexpressing HA-, FLAG-
tagged wild-type (Bag-1L WT) or N-terminal mutant Bag-1L (Bag-1L NMut). The IP was 
performed using anti-HA-tag or IgG control antibodies and an antibody against AR, to evaluate 
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binding. Equal protein loading (1/10th of the input samples) was confirmed by probing for Bag-
1L, AR and Actin expression. 
 
FIGURE 10. The N-terminal mutant of Bag-1L has an elevated AR-mediated transcription 
profile 
A. Heatmap of the expression profiles, shown as DHT-induced log2 fold changes, of vector-
control cells (Vector) or LNCaP cells stably overexpressing wild-type (WT) and N-terminal 
mutant Bag-1L (NMut). B. qRT-PCR validation of select DHT-upregulated genes unique to the 
N-terminal Bag-1L mutant (as shown in (A)). DHT-induced fold changes for the control cells 
(Vector; open bars), Bag-1L wild-type (WT; grey bars) and Bag-1L N-terminal mutant cells 
(NMut; full bars) are shown. Results are the averages of three independent experiments, three 
replicates each ± SD. C. ChIP-qPCR of AR at select enhancer sites of genes upregulated in the 
LNCaP cells overexpressing the Bag-1L GARRPR mutant. DHT-induced fold enrichments over 
inputs are shown for the control cells (Vector; open bars), the Bag-1L wild-type (WT; brown 
bars) and Bag-1L N-terminal mutant cells (NMut; pink bars). Results are the averages of three 
replicates ± SD.  
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